A Phase II Study of the safety, tolerability and antitumor activity of tucatinib in combination with eribulin and trastuzumab in patients with pretreated unresectable locally advanced or metastatic HER2+ breast cancer
Details
Age
Adult
Type of Study
Treatment
Locations
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Elena Shagisultanova, MD, PhD
Study ID
Protocol Number: 22-1407
More information available at ClinicalTrials.gov: NCT05458674
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers